Beurs gesloten -
Andere beurzen
|
Nabeurs 01:59:56 | |||
742,35 USD | +2,29% | 739,45 | -0,39% |
21/01 | Kyverna Therapeutics benoemt Naji Gehchan als Chief Medical, Development Officer | MT |
21/01 | Novo Nordisk: winst zou binnen drie jaar moeten verdubbelen |
Toevoegen aan een lijst 0 geselecteerde | K/w-verhouding | Koers-boekwaarde | PEG | EV/omzet | Beurskap. / EBITDA | Beurskap. / EBIT | Dividendrendement | Kapi. ($) | |
---|---|---|---|---|---|---|---|---|---|
57.77x | 38,65 | 0.5x | 14.92x | 41.72x | 46.91x | +0.72% | 653 mld. | ||
21.23x | 4,966 | -0.43x | 4.11x | 12x | 13.52x | +3.24% | 354 mld. | ||
24.65x | 17,39 | 1.23x | 8.76x | 17.68x | 19.89x | +1.98% | 341 mld. | ||
38.39x | 38,53 | 0.6x | 6.45x | 14.22x | 14.67x | +3.63% | 303 mld. | ||
13.9x | 5,244 | 0x | 4.23x | 10.08x | 11.3x | +3.11% | 248 mld. | ||
16.1x | 5,955 | 1.01x | 3.79x | 9.91x | 11.02x | +3.69% | 236 mld. | ||
24.9x | 4,982 | 0.62x | 4.29x | 13.43x | 13.39x | +2.34% | 206 mld. | ||
17.77x | 4,404 | -0.78x | 4.18x | 10.65x | 11.09x | +3.84% | 197 mld. | ||
14.97x | 1,675 | 0.04x | 3.29x | 8.35x | 10.07x | +6.34% | 149 mld. | ||
29.79x | 22,49 | -1.11x | 5.9x | 10.38x | 13.21x | +3.32% | 146 mld. | ||
16.8x | 1,628 | 0.46x | 2.92x | 9.72x | 10.65x | +3.91% | 128 mld. | ||
883.25x | 6,032 | -9.04x | 4.68x | 12.6x | 16.09x | +3.34% | 114 mld. | ||
-18.16x | 6,647 | 0.1x | 3.2x | 27.56x | 32.15x | +4.24% | 114 mld. | ||
28.49x | 5,909 | 1.53x | 8.78x | 17.75x | 19.16x | +1.32% | 70,72 mld. | ||
15.97x | 3,748 | -0.53x | 2.22x | 6.94x | 7.7x | +4.45% | 67,96 mld. | ||
36.87x | 4,949 | 2.55x | 4.07x | 22.11x | 28.39x | +1.39% | 53,31 mld. | ||
22.67x | 2,009 | 0.5x | 3.71x | 14.82x | 16.45x | +1.67% | 41,58 mld. | ||
53.16x | 0,8862 | -3.01x | 2.34x | 9.88x | 33.22x | +4.86% | 41,06 mld. | ||
47.06x | 6,274 | 1.2x | 9.57x | 37.57x | 39.88x | +0.53% | 38,77 mld. | ||
Gemiddelde | 70,82x | 9,6 | -0,24x | 5,34x | 16,18x | 19,41x | +3,05% | 184,42 mld. | |
Gewogen gemiddelde per kap. | 56,78x | 15,9 | 0,00x | 6,86x | 18,70x | 21,21x | +2,81% |
- Beurs
- Aandelen
- Koers LLY
- Sector Eli Lilly and Company
- Sectorale waarderingen